Including our visitors from overseas.
*** FUND RAISING STATUS: Here we are again heading toward the deadline and not close to meeting our deficit for this coming month. Unfortunately, we have no choice at this time, but to partner with our readers to be able to continue this journey down this rabbit hole. Its been a brutal 4.5 years doing this and we hate to stop when we are so close to the end.
Our deficit is at $80, (thanks to generous donors) and its due in 3 days, so if you benefited in any way, from our blog, and wish to see us continue, then please contribute off to the right at the pay pal button. We thank you deeply for your continued support of our work. God bless and keep you and your family safe and healthy.
, November 16, 2014
Photograph: Getty Images
A new blood test for Alzheimer’s appears to detect the disease as
many as 10 years before clinical diagnosis is possible -- far sooner
than other tests in development.
The test, described publicly for the first time yesterday, could soon be used to identify and treat patients with Alzheimer’s earlier in their disease progression. Those people could participate in clinical trials to help find new treatments. Already, the test distinguishes between patients and healthy elderly with 100 percent accuracy.
“We will need replication and validation, but I’m very optimistic this work will hold,” Dimitrios Kapogiannis, the study’s lead author and a neuroscientist at the National Institute on Aging, said after a presentation at the Society for Neuroscience conference in Washington yesterday.
The blood test is still in the early stages of development and has only been evaluated in 174 individuals, requiring a larger, long-term study before widespread use, the authors said in a statement. NanoSomiX, an Aliso Viejo, California-based biotech company that develops blood assays for neurodegenerative diseases and is sponsoring the study, plans to produce a commercial version of the test, the company said in a separate statement.
At the National Institute on Aging, Kapogiannis and his team identified a single protein in the brain involved in insulin signaling, called IRS-1, that appears to be defective in Alzheimer’s patients.
From the samples, the researchers isolated exosomes, little lipid sacs that bud off cell membranes and carry signals to other cells and tissues. From the resulting pool of exosomes, they identified just those originating in the brain, which contain IRS-1, and measured the levels of the protein.
They found that patients with Alzheimer’s had higher amounts of the inactive form of the protein and lower amounts of the active form than healthy individuals. The diabetics had intermediate levels.
These levels were so consistent that the team could predict whether a blood sample came from an Alzheimer’s patient, healthy individual, or a diabetic -- with no errors. This was true even for samples from Alzheimer’s patients taken 10 years before they were diagnosed.
“We were able to perfectly classify patients and controls,” Kapogiannis said during his presentation.
To contact the reporter on this story: Megan Scudellari in Washington at mscudellari@bloomberg.net
To contact the editors responsible for this story: Crayton Harrison at tharrison5@bloomberg.net Carlos Caminada, Nancy Moran
The test, described publicly for the first time yesterday, could soon be used to identify and treat patients with Alzheimer’s earlier in their disease progression. Those people could participate in clinical trials to help find new treatments. Already, the test distinguishes between patients and healthy elderly with 100 percent accuracy.
“We will need replication and validation, but I’m very optimistic this work will hold,” Dimitrios Kapogiannis, the study’s lead author and a neuroscientist at the National Institute on Aging, said after a presentation at the Society for Neuroscience conference in Washington yesterday.
The blood test is still in the early stages of development and has only been evaluated in 174 individuals, requiring a larger, long-term study before widespread use, the authors said in a statement. NanoSomiX, an Aliso Viejo, California-based biotech company that develops blood assays for neurodegenerative diseases and is sponsoring the study, plans to produce a commercial version of the test, the company said in a separate statement.
Related:
- Most Dementia Patients Get Drugs of Questionable Benefit
- 'Mom Turned Into a Monster': 10,000 Seniors Go Missing in Japan
At the National Institute on Aging, Kapogiannis and his team identified a single protein in the brain involved in insulin signaling, called IRS-1, that appears to be defective in Alzheimer’s patients.
Exosome Pool
The researchers gathered blood samples from 70 individuals with Alzheimer’s disease, 20 cognitively normal elderly with diabetes, and 84 healthy adults. Of the participants, 22 of the Alzheimer’s patients provided samples taken one to 10 years before diagnosis.From the samples, the researchers isolated exosomes, little lipid sacs that bud off cell membranes and carry signals to other cells and tissues. From the resulting pool of exosomes, they identified just those originating in the brain, which contain IRS-1, and measured the levels of the protein.
They found that patients with Alzheimer’s had higher amounts of the inactive form of the protein and lower amounts of the active form than healthy individuals. The diabetics had intermediate levels.
These levels were so consistent that the team could predict whether a blood sample came from an Alzheimer’s patient, healthy individual, or a diabetic -- with no errors. This was true even for samples from Alzheimer’s patients taken 10 years before they were diagnosed.
“We were able to perfectly classify patients and controls,” Kapogiannis said during his presentation.
To contact the reporter on this story: Megan Scudellari in Washington at mscudellari@bloomberg.net
To contact the editors responsible for this story: Crayton Harrison at tharrison5@bloomberg.net Carlos Caminada, Nancy Moran
The article is reproduced in accordance with Section 107 of title 17 of the Copyright Law of the United States relating to fair-use and is for the purposes of criticism, comment, news reporting, teaching, scholarship, and research.
No comments:
Post a Comment